Table GPS-9. Lifetime prevalence (percentage) of drug use among young adults (aged 15 to 34) in nationwide surveys among the general population: last survey available for each Member State

Country

geographical area

 

Year

Ref.

Age range young adults

Sample size young adults

Cannabis (%)

Cocaine (%) (1)

Amphetamines (%) (2)

Ecstasy (%)
(3)

LSD (%)

Belgium

National

 

2001

(5)

15-34

2758

19.2

 

4.0

 

 

Czech Republic

National

 

2004

(2)

18-34

1414

38.3

1.8

4.7

14.6

2.5

Denmark

National

 

2000

(3)

16-34

4141

44.6

4.5

9.6

2.6

1.3

Germany

National

 

2003

(6)

18-34

3775

36.1

5.0

5.4

5.3

3.4

Estonia

National

 

2003

(2)

15-34

646

 

 

 

 

 

Greece

National (except Aegean and Ionian Islands)

 

2004

(3)

15-34

2620

10.8

1.0

0.2

0.6

0.4

Spain

National

 

2003

(5)

15-34

5357

39.0

8.9

4.7

8.3

 

France

Metropolitan France

 

2002

(5)

15-34

724

39.9

3.0

0.1

1.9

1.5

Ireland

National

 

2002-03

(4)

15-34

 

24.0

4.7

4.8

7.1

4.6

Italy

National

 

2003

(2)

15-34

5231

29.9

6.2

2.0

3.3

3.0

Cyprus

National

(4)

2003

(1)

15-34

580

24.5

1.4

0.3

5.9

0.3

Latvia

National

 

2003

(1)

15-34

 

19.6

1.9

5.3

5.0

2.2

Lithuania

National

 

2004

(1)

15-34

1814

13.0

0.7

2.2

2.1

0.5

Luxembourg

National

 

1998

(1)

15-34

 

15.8

0.3

 

1.9

1.3

Hungary

National

 

2003

(2)

18-34

2319

17.4

1.5

4.5

5.6

3.1

Malta

National

 

2001

(1)

18-34

640

4.8

0.9

0.7

1.4

0.5

Netherlands

National

 

2001

(2)

15-34

6687

31.5

5.1

5.1

7.4

1.6

Austria

National

 

2004

(1)

15-34

1754

28.0

2.8

3.5

4.6

1.8

Poland

National

 

2002

(1)

16-34

 

14.7

1.3

4.1

1.5

2.5

Portugal

National

 

2001

(1)

15-34

6406

12.4

1.3

0.6

1.4

0.6

Slovakia

National

 

2004

(2)

15-34

578

28.2

1.7

2.6

7.4

 

Finland

National

 

2004

(6)

15-34

1031

22.0

2.1

4.1

3.3

1.4

Sweden

National

 

2005

(6)

16-34

9522

17.9

 

 

 

 

United Kingdom

England and Wales

 

2004-05

(8)

16-34

9913

41.4

10.5

16.5

12.7

7.3

United Kingdom

Northern Ireland

 

2002-03

(9)

15-34

 

25.1

2.9

7.2

11.4

7.8

United Kingdom

Scotland

 

2003

(10)

16-34

1193

35.9

8.7

16.5

12.5

7.8

United Kingdom

United Kingdom

 

2004

(11)

16-34

 

42.3

11.1

17.9

13.4

9.0

Bulgaria

National

 

2005

(1)

18-34

433

8.7

2.4

2.8

2.6

1.5

Romania

National

 

2004

(1)

15-34

 

2.9

0.7

0.5

0.5

0.3

Norway

National

 

2004

(2)

15-34

1238

25.5

4.3

5.9

3.6

1.7

Notes:

(1) Cocaine in any form.

(2) For Belgium National 2001 and for Metropolitan France 1995: amphetamines and ecstasy.

(3) For Spain: ecstasy and other designer drugs.

(4) Results of this survey should be viewed with caution due to important discrepancies with previous surveys and school surveys results. A new survey with a bigger sample was conducted in 2005.

This table aims to provide an overview of national surveys. Exceptionally, some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates, which are not comparable with estimates for whole countries (or large regions with both urban and rural areas). Athens was included as a reference point for the 1993 survey.

In surveys with small sample sizes results should be interpreted with caution.

Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15-64, young adults: 15-34). In countries where age ranges are more restrictive, prevalence estimates may tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups.

For methods and definitions on population surveys in general, see General population surveys of drug use – methods and definitions.

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

See Table GPS-0.

Data filter | gpstab10-en.xml